A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting

Phase 2

CIN-102A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Sponsor:

CinDome Pharma, Inc.

Code:

NCT05832151

Conditions

Diabetic Gastroparesis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CIN-102 Dose 15mg or 10mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-20. This information was provided to ClinicalTrials.gov by CinDome Pharma, Inc. on 2025-02-28.